Resource Center

www.lls.org/resourcecenter

More to Explore - Information About Blood Cancers for Patients, Families and Healthcare Professionals

The Word:

donate

December 3, 2012 - Update: Autologous Stem Cell Transplantation for Lymphoma and Myeloma

Your order contains  item(s)  View Order

Note: The free Adobe Acrobat Reader® is required to view and print Adobe PDF files, and the free Windows Media Player or RealPlayer is required to listen to the MP3 audio files.

Date: December 03, 2012
Time: 1:00 p.m. - 2:00 p.m. ET
Location: Telephone/Web
Read: Program Slides | Written Transcript
Listen: Presentation | Q&A Session
Access: Virtual Lecture

Topics Covered

  • The role of autologous stem cell transplantation (ASCT) to treat patients with myeloma
  • The role of ASCT to treat patients with lymphoma
  • Side effects management and other quality of life issues for ASCT patients
  • Key ASCT research topics
  • The importance of patient-provider communications

Speakers

Jonathan W. Friedberg, MD, MMSc
Professor of Medicine and Oncology
Chief
, Hematology/Oncology Division
James P. Wilmot Cancer Center
University of Rochester
Rochester, New York

Edward A. Stadtmauer, MD
Professor of Medicine
Leader
, Hematologic Malignancies Research Program
Abramson Cancer Center
University of Pennsylvania
Philadelphia, Pennsylvania

Questions Asked by the Myeloma and Lymphoma Communities

  • How do you find an experienced autologous stem cell transplant center?
  • Is a transplant considered successful or not if a patient makes it a year after transplant and then the disease returns?
  • If a patient gets pneumonia easily and often after a donor transplant, what can he or she ask the doctor about activating his or her stem cells? 
  • If a myeloma patient has renal failure and the autologous stem cell transplant is not effective, what are the treatment options?
  • What type of maintenance could be used to help prolong a remission if a patient can?t use lenalidomide (Revlimid®)? 
  • Do patients receive any drugs prior to stem cell collection that help with the collection of stem cells from the blood? 
  • If stem cells were collected back in 1999, how long would those cells survive?  Would they still be good?  Could they ever be used if needed?  And what is the shelf life? 
  • If someone has been treated with the drug ibritumomab tiuxetan (Zevalin®), is he or she able to have a stem cell transplant?
  • If a patient harvested stem cells, is it better to get a transplant or just stay on Revlimid? 
  • Are there any clinical trials that are following stem cell transplant patients to assess side effects and treatments for them?

Sponsors and Supporters

This program is sponsored by The Leukemia & Lymphoma Society and supported by a grant from Sanofi-Aventis.

last updated on Thursday, July 10, 2014
btn_sharethis

Get Information
& Support

Contact an Information Specialist.